Laura Piqueras has a degree and a PhD in Pharmacy from the University of Valencia. She was awarded an Extraordinary Doctorate Award from the University of Valencia (2005).
Since 2008, she has been the Principal Investigator of competitive national projects financed by the Carlos III Health Institute and regional ones of the Generalitat Valenciana. During his postdoctoral period (2004-2006), she did a stay at the William Harvey Research Institute in London, where her research focused on the study of nuclear receptors (PPAR and RXR) and their role in vascular inflammation and angiogenesis.
Subsequently, she joined INCLIVA within the Juan de la Cierva program and later through the Miguel-Servet Type I and Type II Senior Researchers Program of the Carlos III Health Institute. Her area of research has focused on the study of the cellular and molecular mechanisms that mediate the anti-inflammatory and antiangiogenic actions of different nuclear receptors in pathologies such as abdominal aortic aneurysm, acute myocardial infarction, and obesity.
She is currently a Full Professor in the Department of Pharmacology at the University of Valencia. She teaches undergraduate courses and in the Master’s in Research and Rational Use of Medicines and in the Master’s in Biomedicine and Biotechnology at the University of Valencia. During this period she has directed numerous Doctoral Theses, Final Master’s and Final Degree Projects at INCLIVA and the University of Valencia.
She is also a member of CIBERDEM (Biomedical Network Research Center for Diabetes and Associated Metabolic Diseases), the Spanish Society of Pharmacology and the Spanish Society of Arteriosclerosis.